07:33 AM EDT, 10/09/2024 (MT Newswires) -- Novavax ( NVAX ) said Wednesday that the European Commission granted the marketing authorization for its updated Nuvaxovid COVID-19 vaccine for use in individuals of at least 12 years old.

The company said the approval was based on non-clinical data that showed Nuvaxovid's cross-reactivity across several JN.1 lineage viruses.

Novavax ( NVAX ) said Nuvaxovid's adjuvanted version is allowed for emergency use in the US under an emergency use authorization from the Food and Drug Administration.

Price: 13.10, Change: +0.06, Percent Change: +0.46